Needham Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $26 to $34.
Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $26 to $34.